Background: The obstetric antiphospholipid syndrome (OAPS) is an autoimmune disease defined by the presence of obstetric complications related to antiphospholipid antibodies. EUROAPS project is the biggest published European registry on obstetric antiphospholipid syndrome and it is ongoing.

Objectives: To analyse the clinical features, laboratory data and foetal-maternal outcomes, and follow them up on a cohort of 1100 women with obstetric antiphospholipid syndrome (OAPS).

Methods: Thirty hospitals throughout Europe have collaborated to carry out this registry. Cases with obstetric complaints related to antiphospholipid antibodies (aPL) who tested positive for aPL at least twice were included prospectively and retrospectively. The eight-year survey results are reported.

Results: 1100 women with 3653 episodes were included of which 2553 were historical and 1100 were latest episodes. All cases fulfilled the Sydney classification criteria. According to the laboratory categories: 29.2% were in category 1, 35.7% in category 2, 1.5% in category 3, and 23.6% in category 4.

Conclusion: In this series, recurrent miscarriage is the most frequent poor outcome. To avoid false-negative diagnoses, all laboratory category subsets were needed. OAPS cases have very good foetal-maternal outcomes when treated. Results suggest that we were able to improve our clinical practice to offer better treatment and outcomes to OAPS patients.

REFERENCES

Acknowledgement: Elmina Lefkou, Gerard Espinosa, Sara Tabacco, Luca Marozio, Pier Luigi Meroni, Tania Melnychuk, V Canti, Vittorio Pengo, Beatrice Chighizola, Maria Gerosa, Elisa Picardo, Elisa Llurba, Arseni Merkianian, Bettina Toth, Katharina Bremme, Angelia Tinca.

Disclosure of Interests: Enrique Esteve-Valverde: None declared, Jaume Alijotas-Reig: None declared, Raquel Ferrer-Orivellas: None declared, Luis Sáez-Comet: None declared, Cristina Belizna: None declared, Amelia Rufatti: None declared, Angela Tincani Consultant for: UCB, Pfizer, Abbvie, BMS, Sanofi, Roche, GSK, AlphaSigma, Lilly, Janssen, Celgene, Novartis, Saradecarolis: None declared, Omar Latino: None declared, Ricard Cervera: None declared


THE EUROPEAN REGISTRY ON OBSTETRIC ANTIPHOSPHOLIPID SYNDROME (EUROAPS): A SURVEY OF 1100 CONSECUTIVE CASES

ENHANCING THE QUALITY OF CLINICAL DATA THROUGH DATA CURATION IN PRIMARY SJÖGREN’S SYNDROME

Vasileios Pezoulas1, Themis Exarchos2, Aliki Venetsanopoulou3, Evangelia Zampeli4, Saviana Gandolfo5, Salvatore De Vita6, Fotini N. Skopoulou7, Athanasios Tziofas8, Dimitris Fotiadis1, University of Ioannina, Dept. of Materials Science and Engineering, Ioannina, Greece, 2Iranian University, Dept. of Informatics, Cofu, Greece, 3University of Athens, Dept. of Pathophysiology, Athens, Greece, 4Institute for Systemic Autoimmune and Neurological Diseases, Athens, Greece, 5Udine University, Dept. of Medical and Biological Sciences, Udine, Italy, 6Euroclinic Hospital, Dept. of Internal Medicine and Clinical Immunology, Athens, Greece

Background: Primary Sjögren’s Syndrome (pSS) is a chronic systemic autoimmune disease that is affecting primarily women near the menopausal age, causing exocrine gland dysfunction, with clinical manifestations varying from dry eye and mouth to multi-systemic disorders [1]. The lack of automated means for data quality improvement in pSS cohorts and the huge time effort needed for manual curation, yield data that are irrelevant and incomplete, introducing undesirable implications in their analysis.

Objectives: To enhance the quality of the clinical data in pSS using automated data curation.

Methods: Anonymized clinical data were recruited from 380 patients with pSS from the University of Athens (UoA) cohort (300 patients, mean age 68.79±14.84) and the Harokopio University of Athens (HUA) cohort (80 patients, mean age 59.29±13.92). The features consist of SSS-related measures (see [2] for details). The curation tool produces 3 files: (i) a quality report, including the metadata, the presence of outliers (using the z-score [3]), unknown data types, and missing values, on a feature-based (data imputation [4] is used to fix features with < 50% missing values), (ii) the curated dataset, where the inconsistencies are marked using color notations, and (iii) a standardization report, where the features that share common terminology with those from a reference model [5] (i.e., a set of parameters that describe the pSS minimal requirements) are identified using lexical matching [6].

Results: For the UoA cohort, out of 167 features, 80 were classified as “bad”, 30 with unknown data type, and 12 were marked for outliers (Fig. 1). An example of an outlier was found for the IgM (1370 mg/dL). For the HUA cohort, out of 204 features, 69 were classified as ‘bad’, 5 with unknown data type, and 13 were marked for outliers. The standardization process successfully matched 82 out of 88 (93.18%) pSS-related terms for the UoA cohort and 61 out of 69 (88.4%) terms for the HUA cohort.

Conclusion: Our strategy enhances the quality of the pSS clinical data through data curation and reduces the time effort needed for manual curation by the clinicians. The tool produces re-usable reports that can be used to fix inconsistencies, outliers, missing values, and harmonize pSS clinical data [6].

REFERENCES

Figure 1. An instance of (A) the curated dataset, and (B) the quality assessment report, for the UoA cohort.
SINGLE CELL RNA EXPRESSION IN LUPUS NEPHRITIS COMPARING AFRICAN-AMERICAN AND CAUCASIAN PATIENTS IDENTIFIES DIFFERENTIAL EXPRESSION OF TYPE I INTERFERON PATHWAY

Andrea Fava1, Yui Zhang2, Nir Hacohen3, Deepak Rao4, Matthias Kretzler5, Michael Brenner6, David Wolfe7, Anne Davidson8, Matthias Kretzler4, David Hildeman5, E. Steve Woodle9, Betty Diamond8, Michelle A. Petri1, on behalf of Accelerating Medicine Partnership.

Background: African-American lupus nephritis patients may have a stronger immune response to the disease. For example, CD4 T cells in African-Americans have a higher expression of type 1 interferon pathway activation in infiltrating immune cells. Several other pathways, including calcium and bone homeostasis, and its deficiency has been implicated in the development of SLE and other connective tissue diseases. The study of different murine models has provided a better understanding of these autoimmune phenomena. Pristane-induced lupus (PIL) represents a suitable model to study factors that could influence the induction and/or progression of SLE, including genetic factors.

Objectives: To evaluate the development and evolution of SLE after 1,25(OH)2D supplementation in the PIL model.

Methods: Female BALB/c mice divided into three groups: CO, PIL, and PIL+VD. Lupus was induced in PIL and VD groups using pristane. VD group received a subcutaneous injection of calcitriol [2ug/kg] in PBS-Tween 20 buffer every second day during 180 days. Both groups had arthritis clinical score, edema, and articular nociception was measured. On day 150 after pristane induction, the animals were placed in individual metabolic cages for urine collection for a period of 12h. Protein levels on urine were analyzed using urine test strips. At the end of the experimental period, serum, tibiotarsal joint and kidneys was collected. Hind paws were collected to confirm the development of arthritis by histological analysis with HE staining. The glomerular cellularity was quantified by counting the total cell nuclei per glomerulus on HE slides. Immune complex deposition (IgG and IgM) in kidney was measured by direct immunofluorescence. IL-2, IL-4, IL-6, IFN-γ and TNF-α were measured by Luminox technology in serum. Data was analyzed with ANOVA Two-Way followed by Bonferroni and independent sample t-test. p<0.05 was considered significant. All data are represented as means±SD.

Results: PIL group showed arthritis and kidney injury, characterized by increased proteinuria, glomerular mesangial expansion and inflammation. Moreover, PIL model showed increased levels of IL-6, TNF-α and IFN-γ in serum. VD treatment reduced arthritis incidence compared PIL (42vs85%;p<0.01) at the end of the experimental period. The arthritis clinical score (1.00±1.15vs2.85±1.34;p<0.001) and the hind paws edema (0.20±0.03vs0.24±0.05 mL;p<0.05) in the VD group were also attenuated in relation to the PIL at day 180 after induction. VD was able to reduce synovial hyperplasia (0(0,1)vs2(2,3);p<0.05), erosion in bone (0(0,1)vs2(2,2);p<0.05) and cartilage (110(23,2)vs2(2,3);p<0.05) when compared to the PIL group. Treatment with VD was not able to reduce proteinuria levels (44.28vs47.14 mg/dL), decrease mesangial hypercellularity (31.48±6.5±33.12±3.4±24±24±0.6±2.6±2.6±9.5±15.5±3.7±7.7 deposition in the kidneys. VD supplementation did not alter IL-6, TNF-α, IL-2 and IL-4 cytokine levels, but reduce IFN-γ levels (p<0.01).

Conclusion: VD improves arthritis but does not influence renal injury despite reducing IFN-γ levels. These results support that the role of VD may be different depending on acting site, what could explain different responses according clinical phenotype. Therefore, further investigations of VD are needed to explore the supplementation doses, timing, and the molecular basis in SLE.